Yohei Abe

Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma

Enfortumab vedotin (EV) plus pembrolizumab (EVP) has become a standard first‐line regimen for unresectable locally advanced or metastatic urothelial carcinoma. Further characterization of clinical heterogeneity and toxicity may complement existing Japanese real‐world data.

Darolutamide-based triplet therapy versus androgen receptor pathway inhibitor-based doublet therapy for metastatic castration-sensitive prostate cancer: a real-world analysis using the TriNetX database.

Impact of PI-RADS During Active Surveillance for Prostate Cancer on Pathological Findings at Repeat Biopsy

At one year, a PI-RADS score ≥3 was associated with a higher risk of reclassification, whereas a score ≤2 was associated with a greater likelihood of no cancer on rebiopsy, highlighting the prognostic value of MRI in guiding active surveillance.